Mumbai to Singapore.
A two-stage execution strategy connecting South Asia’s IP generation hub with Singapore’s global liquidity network to execute the first asset-backed scientific transactions.
Stage 01
Mumbai
Syndicate Assembly
Stage 02
Singapore
Global Capital Access
Campaign Architecture
Two-Stage Execution Strategy
From closed-door convening in Mumbai to international liquidity syndication in Singapore.
Stage 01
October 5, 2026 • Mumbai
The Mumbai Convening
Assembly of the founding 40 principal delegates across biopharma leadership, legal counsel, and family offices to ratify legal SPV frameworks and establish initial IP selection protocols.
Chatham House Rule deliberation
Trustee SPV structure sign-off
Ratification of $50M initial target pipeline
BKC, Mumbai, India
Stage 02
TOKEN2049 • Singapore
The Global Liquidity Launch
Presentation of the Scientific Asset Receipts (SARs) framework to international institutional allocators, sovereign wealth entities, and global liquidity pools in Singapore.
Cross-border capital onboarding
3-Layer AI valuation engine launch
Issuance of inaugural Q1 2027 SAR tranche
TOKEN2049 Singapore & Private Institutional Suites
SOLVING THE PRICING BOTTLENECK
The AI-Native Underwriting Engine
Because deep science lacks historical actuarial data, we deploy a continuous, three-layered AI intelligence model to replace static valuation reports with real-time probability pricing.
Vertical 01
Clinical Phase II IP Assets
De-risked therapeutic candidates with validated safety profiles requiring non-dilutive capital to complete multi-center trials.
Allocation Pool
$25M
Vertical 02
Synthetic Bio Foundations
Industrial bio-manufacturing platforms and novel enzyme libraries with clear recurring yield models and patent protection.
Allocation Pool
$15M
Vertical 03
Computational Discovery
AI-driven target discovery platforms holding proprietary structural databases and wet-lab validation loops.
Allocation Pool
$10M
BY INVITATION ONLY
Request a Seat at The Scientific Capital Table
Participation is strictly limited to 40 primary decision-makers across Sovereign Funds, Family Offices, Biopharma CEOs, Market Intermediaries, and Policy Leaders.
